|
시장보고서
상품코드
2125253
경구약 : 시장 동향, 경쟁 구도 및 시장 예측(2034년)Oral Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요 :
- 경구용 의약품 시장은 2025년에 1조 150억 달러로 추정되며, 2034년까지 1조 6,720억 달러에 달할 것으로 전망됩니다. 이러한 성장의 배경에는 전 세계에서 증가하는 만성질환의 부담, 주사제를 대체할 수 있는 자가 투여 가능한 경구 요법에 대한 환자와 의사의 강한 선호, 그리고 경구용 펩티드 및 단백질 전달 기술의 급속한 발전이 있습니다.
- 전 세계 경구용 의약품 시장은 2026-2034년까지의 예측 기간 중 연평균 성장률(CAGR) 5.7%로 성장하고 있습니다.
- 약제 분류별로는 2025년에 심혈관계 약제 부문이 24%의 점유율을 차지하며 경구용 의약품 시장을 주도했습니다.
- 분자 유형별로는 2025년에 저분자 의약품 부문이 79%의 점유율을 차지하며 경구용 의약품 시장을 주도했습니다.
- 제형별로는 2025년에 정제 부문이 44%의 점유율을 차지하며 경구용 의약품 시장을 주도했습니다.
- 방출 유형별로는 2025년에 즉시 방출형 경구약 부문이 55%의 점유율을 차지하며 경구약 시장을 주도했습니다.
- 처방 현황별로는 2025년에 처방전이 필요한 경구용 의약품 부문이 69%의 점유율로 경구용 의약품 시장을 독점했습니다.
- 북미는 2025년에 36%의 점유율을 차지하며 전 세계 경구용 의약품 시장의 매출을 주도했고, 지역별로는 전 세계에서 가장 높은 시장 점유율을 기록했습니다.
경구용 의약품이란 경구 투여용으로 제제화된 의약품으로, 정제, 캡슐, 소프트젤 캡슐, 내복액, 내복 현탁액 등을 포함하며, 급성 및 만성 치료 분야에서 널리 사용되고 있습니다. 경구 투여는 비침습적이며, 무균 상태나 전문 인력을 필요로 하지 않아,환자의 복약 순응도를 높이고 가정에서의 자가 투여를 가능하게 하므로 전 세계에서 가장 널리 이용되는 약물전달 경로로 자리 잡고 있으며, 시장에는 브랜드 의약품, 제네릭 의약품, 그리고 점점 증가하고 있는 생물제제 유래의 제제가 포함되어 있습니다. 이러한 제품들은 진통제·해열제,심혈관계 약물, 중추신경계(CNS) 약물, 항암제, 호흡기계 약물, 기타 치료 분야에 걸쳐 있으며, 저분자 의약품으로 제조될 뿐만 아니라, 흡수 촉진 제형 기술을 통해 가능해진 펩티드계, 단백질계, 핵산계 경구약이라는 확대되고 있는 카테고리로도 제조되고 있습니다. 본 시장은 약물 분류별, 분자 유형별(저분자, 펩티드계, 단백질계, 핵산계 경구용 의약품), 제형별(정제, 캡슐, 소프트젤 캡슐,경구용 액제, 경구용 현탁액), 방출 유형별(즉방성, 서방형, 지속방출성, 제어방출성 제제), 처방 현황별로는 처방약 및 일반의약품(OTC) 경구약으로 구분됩니다. 또한 유통 채널별로는 병원 약국, 소매 약국, 온라인 약국, 기타 채널로 나뉩니다. 고령화 및 만성질환 부담 증가,주사제에서 경구용 바이오의약품으로의 전환 가속화, 경구용 펩티드 및 매크로사이클 전달 기술의 발전, 그리고 제네릭 의약품 및 브랜드 의약품의 제조 능력 지속적 확대에 힘입어, 경구용 의약품 시장은 계속해서 세계 제약 업계에서 가장 크고 핵심적인 부문으로 자리매김하고 있습니다.
경구용 의약품 시장의 주요 성장 동인
- 전 세계 만성질환 부담의 증가와 인구 고령화로 인해 장기적인 경구 유지 요법에 대한 수요가 확대되고 있으며, 세계보건기구(WHO)는 전 세계 60세 이상 인구가 2023년 11억 명에서 2030년까지 14억 명으로 증가할 것으로 예측하고 있습니다.
- 환자와 의사들 사이에서 주사 요법보다 경구 요법을 선호하는 경향이 강해짐에 따라 경구용 바이오의약품의 채택이 가속화되고 있습니다. 대표적인 예로, 2026년 4월 일라이 릴리(Eli Lilly)가 최초의 경구용 저분자 GLP-1 수용체 작용제인 ‘Foundayo(orforglipron)’에 대해 FDA 승인을 획득한 것과,2025년 12월 노보 노르디스크가 체중 관리 약물로 경구용 세마글루타이드 제제 ‘Wegovy’의 승인을 획득한 사례를 들 수 있습니다.
- 경구용 펩티드 및 매크로사이클 전달 기술의 발전으로 인해 정제로 치료 가능한 질환의 범위가 확대되고 있습니다. 그 예로, 2026년 7월 머크(Merck)사가 매크로사이클 펩티드 기술을 기반으로 한 최초의 1일 1회 투여 경구용 PCSK9 억제제 ‘Lipfendra(enlicitide)’에 대해 FDA 승인을 획득한 것을 들 수 있습니다.
- 심혈관 질환, 대사 질환, 종양학, 면역학 등 각 적응증 분야에서 규제 당국의 승인 및 적응증 확대가 가속화됨에 따라 브랜드 의약품 및 제네릭 경구 치료제의 대상 환자층이 증가하고 있습니다.
- 경구 고형 제제의 제조 능력, 서방형·지속 방출 기술, 그리고 경구 생물제제의 제형 플랫폼에 대한 막대한 투자로 인해 전 세계 생산 능력이 확대되고 있습니다.
- 엄격한 생물학적 동등성, GMP 및 품질관리 요건으로 인해 제네릭 의약품의 전반적인 접근성이 확대되고 있는 반면, 브랜드 의약품의 시장 점유율은 규제 당국에 대한 실적이 입증된 유서 깊은 제조사에 집중되어 있습니다.
- 만성질환의 부담 증가, 경구 투여를 선호하는 환자 경향, 경구용 바이오의약품의 혁신, 그리고 제조 능력 확대가 맞물려 2034년까지 시장은 꾸준한 성장을 유지할 것으로 예상됩니다.
경구용 의약품 시장의 성장에 기여하는 요인
시장 촉진요인
전 세계 만성질환 부담의 증가와 고령화
경구용 의약품 시장의 가장 지속적인 촉진요인은 고령화가 진행되는 인구에서 만성 비감염성 질환의 전 세계적 부담이 확대되고 있다는 점입니다. 심혈관 질환, 제2형 당뇨병, 암, 호흡기 질환에는 장기적인 유지 요법이 필요하지만, 이러한 질환들은 임상 현장 밖에서도 매일 자가 투여가 가능하므로 압도적 다수가 경구 제제를 통해 투여되고 있습니다. 세계보건기구(WHO)의 예측에 따르면 전 세계 60세 이상 고령 인구는 2023년 11억 명에서 2030년까지 14억 명으로 증가할 것으로 예상되며,고령자는 의약품 이용률이 높아, 12개월 중 어느 한 기간에 처방약을 복용하고 있는 비율이 85-90%에 달합니다. 선진국 및 신흥 시장을 불문하고 만성질환의 유병률이 높아지고 인구가 고령화됨에 따라 심혈관 질환, 중추신경계 질환, 종양학, 호흡기 질환에 대한 경구용 처방약 조제량은 직접적으로 확대되며, 2034년까지의 시장 성장을 지원할 것으로 보입니다.
주사제보다 경구제를 선호하는 환자 및 의사의 경향이 강해지고 있습니다.
경구 투여로의 구조적 전환에 따라 주요 제약사들의 의약품 개발 우선순위가 재편되고 있습니다. 경구 요법은 생물제제 치료에 수반되는 주사 부담, 콜드 체인 관리, 병원 방문의 필요성을 피할 수 있으며, 만성질환의 장기적인 복약 순응도를 향상시킵니다. 이러한 추세는 파이프라인에 대한 대규모 투자를 촉진하고 있습니다. 노보노르디스크가 2025년 12월 체중 관리용 경구 세마글루티드 정제의 승인을 획득한 데 이어, 일라이 릴리는 2026년 4월,식사나 수분 섭취 제한 없이 복용 가능한 최초의 1일 1회 투여형 경구 저분자 GLP-1 수용체 작용제 ‘파운다요(올포르글리프론)’에 대해 FDA 승인을 획득했습니다. 과거에는 주사제로만 이용 가능했던 치료법이 대사 질환, 심혈관 질환, 면역 질환의 각 적응증에서 경구 제제로 승인됨에 따라 경구약의 제조, 제형, 유통 능력에 대한 수요도 그에 따라 확대되고 있습니다.
시장 제약 요인
견고한 기초 수요가 있음에도 불구하고 경구용 의약품 시장은 중대한 제약에 직면해 있습니다. 많은 지역에서 치열한 제네릭 의약품 경쟁과 의무적인 가격 규제로 인해 특허가 만료된 경구용 치료제의 이익률은 압박을 받고 있습니다. 한편, 서방형, 제어 방출형 및 경구용 생물제제의 개발에 드는 높은 비용과 복잡성은 중소규모 제조사들에게 큰 장벽이 되고 있습니다. 경구용 펩티드 및 단백질 기반 의약품은 소화관내 생체 이용률과 관련된 고유한 과제에 직면해 있으며, 특수한 흡수 촉진 부형제가 필요할 뿐만 아니라 주사제에 비해 투여량이 많고 비용도 높아, 단기적인 상업적 규모로의 확장이 제한될 가능성이 있습니다. 규제 감독이 미흡한 시장에서는 위조 의약품 및 규격 미달 경구용 의약품이 여전히 뿌리 깊은 위험 요인으로 남아 있으며, 환자의 신뢰를 훼손하고 유통을 복잡하게 만들고 있습니다. 지불자의 환급 및 가격 책정에 대한 압박에 더해, 주요 규제 관할 구역 전반에 걸쳐 엄격하고 끊임없이 변화하는 생물학적 동등성 및 품질관리 요건이 개발 기간을 연장시키고 규정 준수 비용을 상승시키고 있습니다. 이러한 가격 책정, 제형의 복잡성 및 규제 장벽이 복합적으로 작용하여, 만성질환의 부담, 경구용 바이오의약품의 혁신, 경구 투여를 선호하는 환자의 경향과 같은 근본적인 촉진요인이 여전히 견고함에도 불구하고 성장 속도를 둔화시키고 있습니다.
자주 묻는 질문
목차
제1장 경구약 시장 : 서론
제2장 경구약 시장 : 개요
제3장 경구약 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제의 동향
제5장 규제 분석
제6장 Porter's Five Forces 분석
제7장 경구약 시장 : 평가
제8장 경구약 시장 : 경쟁 구도
제9장 경구약 시장 : 스타트업 자금조달 및 투자 동향
제10장 경구약 시장 : 기업 개요 및 제품 개요
제11장 KOL의 견해
제12장 프로젝트·어프로치
제13장 DelveInsight 소개
제14장 면책사항 및 문의
KSA 26.09.10Oral Drugs Market Summary
Overview:
- The Oral Drugs market is estimated at USD 1,015 billion in 2025 and is projected to reach USD 1,672 billion by 2034. Growth is anchored in the rising global burden of chronic disease, strong patient and physician preference for self-administered oral therapy over injectable alternatives, and rapid advances in oral peptide and protein delivery technology.
- The global Oral Drugs market is growing at a CAGR of 5.7% during the forecast period from 2026 to 2034.
- By drug class, the cardiovascular drugs segment dominated the Oral Drugs market with a 24% share in 2025.
- By molecule type, the small-molecule drugs segment dominated the Oral Drugs market with a 79% share in 2025.
- By dosage form, the tablets segment dominated the Oral Drugs market with a 44% share in 2025.
- By release type, the immediate-release oral drugs segment dominated the Oral Drugs market with a 55% share in 2025.
- By prescription, the prescription oral drugs segment dominated the Oral Drugs market with a 69% share in 2025.
- North America dominated the global Oral Drugs market revenue with a 36% share in 2025, representing the highest regional market share globally.
Oral drugs are pharmaceutical products formulated for administration by mouth, encompassing tablets, capsules, softgel capsules, oral solutions, and oral suspensions used across acute and chronic therapeutic areas. Because oral administration is non-invasive, does not require sterile conditions or trained personnel, and supports high patient compliance and self-administration at home, it remains the most widely used route of drug delivery worldwide, and the market spans branded, generic, and increasingly biologic-derived formulations. These products span analgesics and antipyretics, cardiovascular drugs, central nervous system (CNS) drugs, oncology drugs, respiratory drugs, and other therapeutic classes, and are manufactured as small-molecule drugs as well as an expanding category of peptide-based, protein-based, and nucleic acid-based oral drugs enabled by absorption-enhancing formulation technologies. The market is organized by drug class; by molecule type, spanning small-molecule, peptide-based, protein-based, and nucleic acid-based oral drugs; by dosage form, including tablets, capsules, softgel capsules, oral solutions, and oral suspensions; by release type, spanning immediate-release, extended-release, sustained-release, and controlled-release formulations; by prescription status, across prescription and over-the-counter (OTC) oral drugs; and by distribution channel, spanning hospital pharmacies, retail pharmacies, online pharmacies, and other channels. Driven by an aging population and rising chronic disease burden, the accelerating shift from injectable to oral biologic therapies, advances in oral peptide and macrocycle delivery technology, and continued expansion of generic and branded manufacturing capacity, the oral drugs market remains the largest and most foundational segment of the global pharmaceutical industry.
Oral Drugs Market Key Growth Drivers
- The rising global burden of chronic disease and an aging population is expanding demand for long-term oral maintenance therapy, with the World Health Organization projecting the global population aged 60 and older to rise from 1.1 billion in 2023 to 1.4 billion by 2030.
- Growing patient and physician preference for oral over injectable therapy is accelerating adoption of oral biologics, exemplified by Eli Lilly's FDA approval of Foundayo (orforglipron), the first oral small-molecule GLP-1 receptor agonist, in April 2026, and Novo Nordisk's oral semaglutide Wegovy pill, approved for weight management in December 2025.
- Advances in oral peptide and macrocycle delivery technology are widening the range of conditions treatable by pill, illustrated by Merck's July 2026 FDA approval of Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor built on macrocyclic peptide technology.
- Accelerating regulatory approvals and label expansions across cardiovascular, metabolic, oncology, and immunology indications are increasing the addressable population for branded and generic oral therapies.
- Heavy investment in oral solid dosage manufacturing capacity, controlled- and extended-release technology, and oral biologic formulation platforms is expanding global production capabilities.
- Stringent bioequivalence, GMP, and quality-control requirements are concentrating branded market share among established manufacturers with proven regulatory track records, even as generics broaden overall access.
- The convergence of chronic disease burden, patient preference for the oral route, oral biologic innovation, and expanding manufacturing capacity is expected to sustain steady growth in the market through 2034.
Key Companies in Oral Drugs Market
The competitive landscape is led by the following active manufacturers:
- Pfizer Inc.
- Novo Nordisk A/S
- Merck & Co., Inc.
- Eli Lilly and Company
- AbbVie Inc.
- AstraZeneca PLC
- Bristol Myers Squibb
- Gilead Sciences, Inc.
- Johnson & Johnson
- Roche Holding AG
Factors Contributing to the Growth of the Oral Drugs Market
Market Drivers
Rising Global Burden of Chronic Disease and an Aging Population
The most durable driver of the Oral Drugs market is the expanding global burden of chronic, non-communicable disease among an aging population. Cardiovascular disease, type 2 diabetes, cancer, and respiratory illness require long-term maintenance therapy that is overwhelmingly delivered through oral formulations because they support daily self-administration outside the clinical setting. The World Health Organization projects the global population aged 60 years and older will rise from 1.1 billion in 2023 to 1.4 billion by 2030, and older adults report high medicine utilization, with 85 to 90 percent taking a prescription medicine within any 12 months. As chronic disease prevalence rises and populations age across developed and emerging markets alike, the volume of oral prescriptions dispensed for cardiovascular, CNS, oncology, and respiratory conditions expands directly, anchoring market growth through 2034.
Growing Patient and Physician Preference for Oral Over Injectable Therapy
A structural shift toward oral administration is reshaping drug development priorities across major pharmaceutical companies. Oral therapy avoids the injection burden, cold-chain handling, and clinic visits associated with biologic treatment, improving long-term adherence in chronic disease. This preference is driving substantial pipeline investment: Eli Lilly received FDA approval in April 2026 for Foundayo (orforglipron), the first once-daily oral small-molecule GLP-1 receptor agonist that can be taken without food or water restrictions, following Novo Nordisk's December 2025 approval of an oral semaglutide pill for weight management. As oral versions of therapies once available only as injectables reach approval across metabolic, cardiovascular, and immunology indications, demand for oral drug manufacturing, formulation, and distribution capacity expands correspondingly.
Market Restraints
Despite strong underlying demand, the Oral Drugs market faces material constraints. Intense generic competition and mandatory price controls in many geographies compress margins on off-patent oral therapies, while the high cost and complexity of developing extended-release, controlled-release, and oral biologic formulations create meaningful barriers for smaller manufacturers. Oral peptide and protein-based drugs face inherent bioavailability challenges in the gastrointestinal tract, requiring specialized absorption-enhancing excipients and larger, more expensive doses relative to injectable equivalents, which can limit near-term commercial scale-up. Counterfeit and substandard oral medicines remain a persistent risk in markets with weaker regulatory oversight, undermining patient trust and complicating distribution. Reimbursement and pricing pressure from payers, together with stringent and evolving bioequivalence and quality-control requirements across major regulatory jurisdictions, lengthen development timelines and raise compliance costs. Together, these pricing, formulation-complexity, and regulatory barriers temper the pace of growth, even as the underlying drivers of chronic disease burden, oral biologic innovation, and patient preference for the oral route remain firmly intact.
Oral Drugs Market Segment Analysis
The oral drugs market by drug class (analgesics and antipyretics, cardiovascular drugs, central nervous system (cns) drugs, oncology drugs, respiratory drugs, others), molecule type (small-molecule drugs, peptide-based oral drugs, protein-based oral drugs, nucleic acid-based oral drugs, others), dosage form (tablets, capsules, softgel capsules, oral solutions, oral suspensions, others), release type (immediate-release, extended-release, sustained-release, controlled-release, others), prescription (prescription oral drugs, over-the-counter (otc) oral drugs), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, others), and geography (North America, Europe, Asia-Pacific, and Rest of World).
By Drug Class
Dominant Subsegment: Cardiovascular Drugs.
The cardiovascular drugs segment accounted for 24% of the Oral Drugs market in 2025. Cardiovascular drugs are the leading drug class because hypertension, dyslipidemia, and coronary artery disease affect an enormous and growing share of the aging global population, and lifelong daily oral maintenance therapy, including statins, antihypertensives, and anticoagulants, generates very high recurring prescription volumes. The category is being reinforced by formulation innovation, including Merck's July 2026 approval of Lipfendra (enlicitide), the first oral PCSK9 inhibitor, which extends oral treatment to patients previously reliant on injectable cholesterol therapy. Widespread generic availability, well-established prescribing guidelines, and broad payer coverage sustain great, dependable demand for cardiovascular oral drug manufacturing. While oncology drugs are the fastest-growing drug class, propelled by expanding targeted and oral small-molecule oncology therapies, the sheer prevalence and chronicity of cardiovascular disease secure the segment's leadership across the forecast period.
By Molecule Type
Dominant Subsegment: Small-Molecule Drugs.
The small-molecule drugs segment accounted for 79% of the Oral Drugs market in 2025. Small-molecule drugs dominate molecule type because they are chemically stable in the gastrointestinal tract, straightforward to manufacture at scale, and compatible with well-established generic and branded tablet and capsule production infrastructure, making them the default modality across essentially every therapeutic class. The category benefits from decades of established manufacturing know-how, extensive patent-driven generic competition, and predictable regulatory pathways. At the same time, peptide-based oral drugs are the fastest-growing molecule type, propelled by breakthroughs such as Eli Lilly's oral GLP-1 Foundayo and Merck's macrocyclic peptide PCSK9 inhibitor Lipfendra, both approved in 2026, which demonstrate that peptide chemistry can now achieve reliable oral bioavailability. Protein-based and nucleic acid-based oral drugs remain in an earlier stage but represent a meaningful long-term opportunity as absorption-enhancing formulation technology matures. Nonetheless, the scale, cost advantage, and manufacturing maturity of small-molecule drugs secure their leadership across the forecast period.
Oral Drugs Market Region Analysis
Dominant Region: North America
North America accounted for 36% of the global Oral Drugs market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a large, aging patient population with high chronic-disease prevalence, extensive insurance and pharmacy-benefit infrastructure, and the concentration of major pharmaceutical manufacturers and their newest oral therapies within the United States. North America hosts the largest branded and generic oral drug manufacturing base and benefits from rapid regulatory pathways at the FDA that have brought landmark oral therapies, including Eli Lilly's Foundayo and Merck's Lipfendra, to market in 2026. Strong reimbursement structures, well-developed retail and online pharmacy networks, and continued investment in oral biologic manufacturing capacity anchor the region's continued leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Oral Drugs market. The region's elevated CAGR is driven by rising chronic-disease incidence, expanding healthcare access and insurance coverage, and rapid growth of domestic generic and branded pharmaceutical manufacturing across China, Japan, India, South Korea, and Australia. China continues to scale domestic oral drug production and streamline regulatory review, Japan sustains a large and aging patient base with strong per-capita prescribing, and India leverages low-cost, high-volume generic tablet and capsule manufacturing to serve both domestic and export markets. Rising government healthcare investment, growing middle-class access to branded therapy, and expanding local production of complex oral formulations position Asia-Pacific as the principal source of incremental market growth over the forecast period.
Regional Commentary
North America
North America accounted for 36% of the global Oral Drugs market revenue in 2025. The United States dominates on the strength of its aging and chronically ill patient population, deep pharmaceutical R&D and manufacturing base, FDA regulatory leadership, and rapid uptake of newly approved oral biologic therapies, while robust reimbursement and well-developed retail and online pharmacy infrastructure reinforce its leadership.
Europe
Europe is a large and mature regional market, supported by established EMA regulatory frameworks, strong generic manufacturing capacity across Germany, France, the United Kingdom, Italy, and Spain, and universal healthcare systems that sustain high chronic-disease treatment rates. Continued expansion of oral biologic access and generics competition reinforce the region's role as a major consumer and producer of oral pharmaceuticals.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising chronic-disease incidence, expanding healthcare infrastructure and insurance coverage, and rapid scale-up of domestic generic and branded manufacturing across China, Japan, India, South Korea, and Australia. China's manufacturing expansion, Japan's large aging population, and India's low-cost generic production are accelerating regional market growth.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare access, rising chronic-disease prevalence, growing local generic manufacturing, and efforts to align regulatory frameworks with international GMP standards are gradually broadening access to both branded and generic oral therapies across the region.
Oral Drugs Market Competitive Landscape
The Oral Drugs market is classified as Moderately Fragmented. A group of large, diversified pharmaceutical companies with global manufacturing scale and broad oral portfolios, including Pfizer, Merck, Johnson & Johnson, and Roche, anchor the branded top tier, while companies such as Novo Nordisk, Eli Lilly, and AbbVie compete intensely through next-generation oral biologic and peptide innovation, and thousands of generic manufacturers compete on cost and volume across off-patent categories, increasing competition throughout the value chain.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Moderately fragmented, with large diversified innovators leading branded categories and a broad base of generic manufacturers competing on cost and volume.
- Leading players: Pfizer, Merck, Johnson & Johnson, and Roche anchor the branded top tier through diversified oral portfolios and global manufacturing scale.
- Innovation leadership: Novo Nordisk and Eli Lilly lead oral peptide and GLP-1 innovation, while Merck advances oral macrocyclic peptide technology in cardiometabolic disease.
- Geographic reach: Leaders operate global manufacturing and distribution networks spanning branded and generic production across North America, Europe, and Asia-Pacific.
- Portfolio breadth: Top players offer oral therapies spanning cardiovascular, metabolic, oncology, CNS, immunology, and infectious-disease indications.
- Formulation technology: Extended-release and controlled-release platforms, and absorption-enhancing peptide and macrocycle delivery technology, are decisive competitive advantages.
- Strategic partnerships: Licensing and co-development agreements around oral peptide and biologic delivery technology, such as Eli Lilly's license of orforglipron from Chugai Pharmaceutical, extend innovation pipelines.
- M&A and pipeline investment: Active investment in oral biologic and peptide programs across major pharmaceutical companies is reshaping competitive positioning in metabolic and cardiovascular disease.
- Manufacturing capabilities: Large-scale tablet, capsule, and softgel production lines, together with specialized oral biologic formulation capacity, are key competitive moats.
- Innovation focus: Oral GLP-1 and PCSK9 therapies, extended-release reformulation of established drugs, and early-stage oral protein and nucleic acid-based drug candidates.
Oral Drugs Market Recent Developmental Activities
In April 2026, Eli Lilly and Company received FDA approval for Foundayo (orforglipron), the first once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, with no food or water restrictions. Strategic significance: Establishes a new oral biologic category in obesity treatment and expands convenient, self-administered alternatives to injectable GLP-1 therapy.
In July 2026, Merck & Co., Inc., received FDA approval for Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, built on macrocyclic peptide technology, to reduce LDL-cholesterol in adults with hypercholesterolemia. Strategic significance: Extends oral peptide-based therapy into cardiovascular disease and demonstrates the commercial viability of oral macrocyclic peptide formulation technology.
Oral Drugs Market Segmentation
Oral Drugs Market by Drug Class
- Analgesics and Antipyretics
- Cardiovascular Drugs
- Central Nervous System (CNS) Drugs
- Oncology Drugs
- Respiratory Drugs
- Others
Oral Drugs Market by Molecule Type
- Small-Molecule Drugs
- Peptide-Based Oral Drugs
- Protein-Based Oral Drugs
- Nucleic Acid-Based Oral Drugs
- Others
Oral Drugs Market by Dosage Form
- Tablets
- Capsules
- Softgel Capsules
- Oral Solutions
- Oral Suspensions
- Others
Oral Drugs Market by Release Type
- Immediate-Release Oral Drugs
- Extended-Release Oral Drugs
- Sustained-Release Oral Drugs
- Controlled-Release Oral Drugs
- Others
Oral Drugs Market by Prescription
- Prescription Oral Drugs
- Over-the-Counter (OTC) Oral Drugs
Oral Drugs Market by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Oral Drugs Market by Geography
- North America Oral Drugs Market
- United States Oral Drugs Market Size in USD million (2023-2034)
- Canada Oral Drugs Market Size in USD million (2023-2034)
- Mexico Oral Drugs Market Size in USD million (2023-2034)
- Europe Oral Drugs Market
- Germany Oral Drugs Market Size in USD million (2023-2034)
- United Kingdom Oral Drugs Market Size in USD million (2023-2034)
- France Oral Drugs Market Size in USD million (2023-2034)
- Italy Oral Drugs Market Size in USD million (2023-2034)
- Spain Oral Drugs Market Size in USD million (2023-2034)
- Rest of Europe Oral Drugs Market Size in USD million (2023-2034)
- Asia-Pacific Oral Drugs Market
- China Oral Drugs Market Size in USD million (2023-2034)
- Japan Oral Drugs Market Size in USD million (2023-2034)
- India Oral Drugs Market Size in USD million (2023-2034)
- Australia Oral Drugs Market Size in USD million (2023-2034)
- South Korea Oral Drugs Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Oral Drugs Market Size in USD million (2023-2034)
- Rest of the World (RoW) Oral Drugs Market
- Middle East Oral Drugs Market Size in USD million (2023-2034)
- Africa Oral Drugs Market Size in USD million (2023-2034)
- South America Oral Drugs Market Size in USD million (2023-2034)
Key Takeaways from the Oral Drugs Market Report Study
- Market size analysis for the current Oral Drugs market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global Oral Drugs market.
- Various opportunities available for competitors in the Oral Drugs market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current Oral Drugs market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for Oral Drugs market growth in the future?
Target audience who can benefit from this Oral Drugs market report study
- Oral Drugs product providers
- Research organizations and consulting companies
- Neurodegenerative disease therapeutics-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in Oral Drugs
- Various end-users who want to know more about the Oral Drugs market and the latest technological developments in the Oral Drugs market.
Frequently Asked Questions:
Q1. What is the growth rate of the Oral Drugs market?
The Oral Drugs market is projected to expand at a CAGR of 5.7% during the forecast period from 2026-2034.
Q2. What is the market size of the Oral Drugs market?
The Oral Drugs market is estimated at USD 1,015 billion in 2025 and is projected to reach USD 1,672 billion by 2034.
Q3. Which region dominates the Oral Drugs market?
North America dominated the Oral Drugs market with a 36% share of global revenue in 2025, supported by a large aging patient population, extensive insurance and pharmacy-benefit infrastructure, FDA regulatory leadership, and the concentration of major pharmaceutical manufacturers. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Oral Drugs market?
The principal drivers are the rising global burden of chronic disease and an aging population; growing patient and physician preference for oral over injectable therapy, illustrated by the 2026 approvals of Eli Lilly's Foundayo and Merck's Lipfendra; advances in oral peptide, protein, and macrocycle delivery technology; accelerating regulatory approvals and label expansions; and continued expansion of generic and branded oral manufacturing capacity.
Q5. Who are the major players in the Oral Drugs market?
The major players include Pfizer Inc., Novo Nordisk A/S, Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., AstraZeneca PLC, Bristol Myers Squibb, Gilead Sciences, Inc., Johnson & Johnson, and Roche Holding AG, among other active manufacturers profiled in the Competitive Landscape section. Pfizer, Merck, Johnson & Johnson, and Roche lead through diversified oral portfolios and global manufacturing scale, while Novo Nordisk and Eli Lilly lead oral peptide and GLP-1 innovation.
Table of Contents
1. Oral Drugs Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Oral Drugs Market Executive Summary
- 2.1 Market at a Glance
3. Oral Drugs Market Key Factors Analysis
- 3.1 Oral Drugs Market Drivers
- 3.1.1 Rising Chronic Disease Burden and Aging Population
- 3.1.2 Preference for Oral Over Injectable Therapy
- 3.1.3 Advances in Oral Peptide and Protein Delivery
- 3.1.4 Regulatory Approvals and Label Expansions
- 3.2 Oral Drugs Market Restraints and Challenges
- 3.2.1 Generic Competition and Pricing Pressure
- 3.2.2 Bioavailability Challenges in Oral Biologics
- 3.2.3 Regulatory and Quality Compliance Complexity
- 3.3 Oral Drugs Market Opportunities
- 3.3.1 Oral GLP-1 and PCSK9 Therapy Expansion
- 3.3.2 Emerging-Market Generic Manufacturing Growth
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Oral Drugs Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Oral Drugs Market Assessment
- 7.1 By Drug Class
- 7.1.1 Analgesics and Antipyretics
- 7.1.2 Cardiovascular Drugs
- 7.1.3 Central Nervous System (CNS) Drugs
- 7.1.4 Oncology Drugs
- 7.1.5 Respiratory Drugs
- 7.1.6 Others
- 7.2 By Molecule Type
- 7.2.1 Small-Molecule Drugs
- 7.2.2 Peptide-Based Oral Drugs
- 7.2.3 Protein-Based Oral Drugs
- 7.2.4 Nucleic Acid-Based Oral Drugs
- 7.2.5 Others
- 7.3 By Dosage Form
- 7.3.1 Tablets
- 7.3.2 Capsules
- 7.3.3 Softgel Capsules
- 7.3.4 Oral Solutions
- 7.3.5 Oral Suspensions
- 7.3.6 Others
- 7.4 By Release Type
- 7.4.1 Immediate-Release Oral Drugs
- 7.4.2 Extended-Release Oral Drugs
- 7.4.3 Sustained-Release Oral Drugs
- 7.4.4 Controlled-Release Oral Drugs
- 7.4.5 Others
- 7.5 By Prescription
- 7.5.1 Prescription Oral Drugs
- 7.5.2 Over-the-Counter (OTC) Oral Drugs
- 7.6 By Distribution Channel
- 7.6.1 Hospital Pharmacies
- 7.6.2 Retail Pharmacies
- 7.6.3 Online Pharmacies
- 7.6.4 Others
- 7.7 By Geography
- 7.7.1 North America
- 7.7.1.1 United States Oral Drugs Market Size in USD million (2023-2034)
- 7.7.1.2 Canada Oral Drugs Market Size in USD million (2023-2034)
- 7.7.1.3 Mexico Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2 Europe
- 7.7.2.1 Germany Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2.2 United Kingdom Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2.3 France Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2.4 Italy Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2.5 Spain Oral Drugs Market Size in USD million (2023-2034)
- 7.7.2.6 Rest of Europe Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3 Asia-Pacific
- 7.7.3.1 China Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3.2 Japan Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3.3 India Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3.4 Australia Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3.5 South Korea Oral Drugs Market Size in USD million (2023-2034)
- 7.7.3.6 Rest of Asia-Pacific Oral Drugs Market Size in USD million (2023-2034)
- 7.7.4 Rest of World
- 7.7.4.1 Middle East Oral Drugs Market Size in USD million (2023-2034)
- 7.7.4.2 Africa Oral Drugs Market Size in USD million (2023-2034)
- 7.7.4.3 South America Oral Drugs Market Size in USD million (2023-2034)
- 7.7.1 North America
8. Oral Drugs Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Oral Drugs Market Startup Funding and Investment Trends
10. Oral Drugs Market Company and Product Profiles
- 10.1 Pfizer Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 Novo Nordisk A/S
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 Merck & Co., Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Eli Lilly and Company
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 AbbVie Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 AstraZeneca PLC
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 Bristol Myers Squibb
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 Gilead Sciences, Inc.
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 Johnson & Johnson
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
10. Roche Holding AG
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
